#Germany #Düsseldorf #Parkinson's #Neuraxpharm #Dizlin

Neuraxpharm and Dizlin Pharmaceuticals Unveil Groundbreaking Parkinson's Treatment

On July 8, 2025, Neuraxpharm Group and Dizlin Pharmaceuticals AB announced a strategic co-development agreement aimed at creating a revolutionary therapy for advanced Parkinson's disease (PD) — Infudopa SubC®. This collaboration signifies a remarkable step forward in addressing the unmet needs of patients affected by this debilitating condition.

A Pioneering Drug-Device Solution

Infudopa SubC® is designed as a user-friendly, wearable drug-device therapy that allows for continuous drug delivery, thereby providing patients with an enhanced level of autonomy in managing their condition. Unlike traditional oral medications that may fall short in effectiveness as the disease progresses, this innovative solution enables flexible dosing options through a subcutaneous infusion pump. Patients can enjoy a more stable and consistent level of medication, addressing the disruptive motor fluctuations often experienced during advanced stages of Parkinson's.

With PD being the fastest-growing neurological disorder globally, currently affecting over 10 million individuals, the demand for effective treatment options has never been more urgent. The prevalence of Parkinson’s disease is projected to double by 2050. Infudopa SubC® aims to change the trajectory of care for these patients by offering a practical and adaptable alternative in their treatment regimens, ultimately empowering them to lead more independent lives.

A Commitment to Transformation

CEO of Neuraxpharm, Dr. Jörg-Thomas Dierks, expressed his enthusiasm for the partnership, stating that they are committed to revolutionizing how Parkinson's disease is treated.